In late 2023, a group of senior British government officials formed an internal opposition known as the “Rebel Alliance” to resist the expansion of Palantir, a major US software company seeking a landmark contract with England’s National Health Service (NHS). The company was pursuing a £330 million, seven-year deal to develop the NHS’s Federated Data Platform (FDP), which would integrate disparate health data systems across the service. Despite their efforts, the group was unsuccessful in blocking the contract, but the controversy surrounding Palantir’s involvement continues to raise political and ethical questions as the contract’s midterm review approaches in 2027.
Palantir entered the UK public sector during the Covid-19 pandemic, providing its Foundry software to manage logistics for ventilators, personal protective equipment, and vaccines at a nominal cost. This early intervention paved the way for a £23.5 million contract in December 2020 and ultimately the larger FDP agreement. The FDP was intended to address longstanding challenges by enabling interoperability across NHS data systems, allowing for real-time visibility into hospital operations and patient care metrics.
Critics have questioned the integrity of the procurement process, arguing that it was heavily influenced by Palantir’s existing technology and relationships within the NHS. Several UK-based bidders reportedly withdrew as the tender appeared tailored to match Palantir’s capabilities. Documentation from the bidding process contained early versions of Palantir’s software features, and the language used in the tender was said to favor the US company, according to sources familiar with the negotiations.
The contract also sparked concerns about data sovereignty and geopolitical implications. Palantir’s ties to US government agencies, including Immigration and Customs Enforcement and the Israel Defense Forces, have added to unease about its role in critical UK infrastructure. Several European countries, including France, Germany, and Switzerland, have recently reduced or eliminated their reliance on Palantir due to similar apprehensions, seeking to develop domestic alternatives instead.
Inside the UK government, debates continue over the balance between cost efficiency, strategic autonomy, and ethical considerations. Some officials worry about the potential risks of placing significant NHS data management in the hands of a foreign provider, while Palantir executives emphasize the company’s commitment to liberal democratic values and argue that all data remains hosted within the UK. They also highlight performance metrics, claiming the FDP has contributed to 110,000 additional operations, a 15 percent reduction in discharge delays, and an overall decrease of 800,000 in patient waiting lists.
However, independent analyses indicate that these improvements have been uneven, with some trusts experiencing declines after adopting the system. Critics describe the FDP as a database with limited functionality rather than a truly integrated platform capable of transforming NHS operations.
The controversy extends into broader concerns about the UK’s approach to technology procurement and innovation policy. The government has expressed intentions to prioritize contracts with British firms to stimulate domestic growth in critical sectors, reflecting growing anxiety about dependence on foreign digital providers. Some industry observers argue the Palantir contract has undercut the UK market, dissuading local start-ups such as Faculty from continuing work with the NHS.
As political and public pressure intensifies, UK ministers are reportedly considering the option to terminate the Palantir contract at the earliest opportunity permitted under its terms in 2027. Behind the scenes, officials are assessing the technical feasibility of removing Palantir’s technology from NHS systems without disrupting care delivery.
Louis Mosley, Palantir UK’s chief executive, acknowledges the challenges but insists the company remains focused on demonstrating the value of its software to public services and patients. “Clearly, we are in a moment where there appears to be a risk that political considerations subsume practical ones,” Mosley said, emphasizing that any decision to end the contract prematurely would have implications for service delivery.
The outcome of this ongoing debate will likely have significant consequences for the UK’s digital health strategy and the future role of international technology providers within public sector infrastructure.